nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoposide—Topoisomerase Inhibitors—Epirubicin—testicular cancer	0.205	0.519	CiPCiCtD
Etoposide—Topoisomerase Inhibitors—Doxorubicin—testicular cancer	0.19	0.481	CiPCiCtD
Etoposide—urinary bladder cancer—testicular cancer	0.061	0.202	CtDrD
Etoposide—prostate cancer—testicular cancer	0.0596	0.198	CtDrD
Etoposide—muscle cancer—testicular cancer	0.0516	0.171	CtDrD
Etoposide—germ cell cancer—testicular cancer	0.0464	0.154	CtDrD
Etoposide—GSTP1—Chlorambucil—testicular cancer	0.0419	0.172	CbGbCtD
Etoposide—lung cancer—testicular cancer	0.0417	0.138	CtDrD
Etoposide—sarcoma—testicular cancer	0.0412	0.137	CtDrD
Etoposide—GSTT1—Carboplatin—testicular cancer	0.0217	0.0889	CbGbCtD
Etoposide—GSTT1—Cisplatin—testicular cancer	0.0185	0.076	CbGbCtD
Etoposide—ABCC6—Dactinomycin—testicular cancer	0.0185	0.076	CbGbCtD
Etoposide—GSTP1—Carboplatin—testicular cancer	0.0135	0.0555	CbGbCtD
Etoposide—ABCC6—Vinblastine—testicular cancer	0.0116	0.0476	CbGbCtD
Etoposide—GSTP1—Cisplatin—testicular cancer	0.0116	0.0475	CbGbCtD
Etoposide—ABCC6—Cisplatin—testicular cancer	0.0106	0.0436	CbGbCtD
Etoposide—TOP2A—Epirubicin—testicular cancer	0.00714	0.0293	CbGbCtD
Etoposide—ABCC6—Doxorubicin—testicular cancer	0.00713	0.0292	CbGbCtD
Etoposide—ABCC1—Dactinomycin—testicular cancer	0.00546	0.0224	CbGbCtD
Etoposide—ABCC10—Doxorubicin—testicular cancer	0.00544	0.0223	CbGbCtD
Etoposide—ABCC10—Methotrexate—testicular cancer	0.00527	0.0216	CbGbCtD
Etoposide—ABCC3—Cisplatin—testicular cancer	0.00511	0.021	CbGbCtD
Etoposide—PTGS1—Ifosfamide—testicular cancer	0.00398	0.0163	CbGbCtD
Etoposide—ABCC1—Epirubicin—testicular cancer	0.00396	0.0162	CbGbCtD
Etoposide—TOP2A—Doxorubicin—testicular cancer	0.00379	0.0156	CbGbCtD
Etoposide—ABCG2—Dactinomycin—testicular cancer	0.00366	0.015	CbGbCtD
Etoposide—ABCC3—Doxorubicin—testicular cancer	0.00342	0.014	CbGbCtD
Etoposide—ABCC1—Vinblastine—testicular cancer	0.00342	0.014	CbGbCtD
Etoposide—ABCC3—Methotrexate—testicular cancer	0.00332	0.0136	CbGbCtD
Etoposide—ABCC2—Carboplatin—testicular cancer	0.00272	0.0111	CbGbCtD
Etoposide—ABCC2—Vinblastine—testicular cancer	0.00253	0.0104	CbGbCtD
Etoposide—ABCG2—Carboplatin—testicular cancer	0.00246	0.0101	CbGbCtD
Etoposide—CYP3A5—Ifosfamide—testicular cancer	0.00239	0.00981	CbGbCtD
Etoposide—ABCC2—Cisplatin—testicular cancer	0.00232	0.00952	CbGbCtD
Etoposide—CYP2C8—Ifosfamide—testicular cancer	0.0023	0.00943	CbGbCtD
Etoposide—PTGS2—Cisplatin—testicular cancer	0.00229	0.00941	CbGbCtD
Etoposide—ABCC1—Doxorubicin—testicular cancer	0.0021	0.00862	CbGbCtD
Etoposide—ABCG2—Cisplatin—testicular cancer	0.0021	0.00861	CbGbCtD
Etoposide—ABCC1—Methotrexate—testicular cancer	0.00204	0.00835	CbGbCtD
Etoposide—ABCC2—Doxorubicin—testicular cancer	0.00156	0.00638	CbGbCtD
Etoposide—ABCC2—Methotrexate—testicular cancer	0.00151	0.00618	CbGbCtD
Etoposide—ABCG2—Doxorubicin—testicular cancer	0.00141	0.00577	CbGbCtD
Etoposide—ABCG2—Methotrexate—testicular cancer	0.00136	0.00559	CbGbCtD
Etoposide—ABCB1—Dactinomycin—testicular cancer	0.00132	0.00541	CbGbCtD
Etoposide—CYP3A4—Ifosfamide—testicular cancer	0.000932	0.00382	CbGbCtD
Etoposide—ABCB1—Vinblastine—testicular cancer	0.000826	0.00339	CbGbCtD
Etoposide—ABCB1—Cisplatin—testicular cancer	0.000757	0.00311	CbGbCtD
Etoposide—ABCB1—Doxorubicin—testicular cancer	0.000507	0.00208	CbGbCtD
Etoposide—CYP3A4—Vinblastine—testicular cancer	0.000495	0.00203	CbGbCtD
Etoposide—ABCB1—Methotrexate—testicular cancer	0.000491	0.00202	CbGbCtD
Etoposide—TOP2B—embryo—testicular cancer	0.000467	0.0636	CbGeAlD
Etoposide—TOP2B—seminal vesicle—testicular cancer	0.000438	0.0597	CbGeAlD
Etoposide—TOP2B—gonad—testicular cancer	0.000317	0.0432	CbGeAlD
Etoposide—CYP3A4—Doxorubicin—testicular cancer	0.000304	0.00125	CbGbCtD
Etoposide—GSTP1—embryo—testicular cancer	0.000292	0.0398	CbGeAlD
Etoposide—GSTP1—seminal vesicle—testicular cancer	0.000274	0.0374	CbGeAlD
Etoposide—ABCC10—seminal vesicle—testicular cancer	0.000274	0.0374	CbGeAlD
Etoposide—TOP2B—female gonad—testicular cancer	0.000257	0.0351	CbGeAlD
Etoposide—TOP2B—testis—testicular cancer	0.000228	0.0311	CbGeAlD
Etoposide—GSTP1—gonad—testicular cancer	0.000198	0.027	CbGeAlD
Etoposide—ABCC10—gonad—testicular cancer	0.000198	0.027	CbGeAlD
Etoposide—ABCC1—seminal vesicle—testicular cancer	0.000194	0.0264	CbGeAlD
Etoposide—TOP2A—female gonad—testicular cancer	0.000189	0.0258	CbGeAlD
Etoposide—TOP2A—Vindesine—Vinblastine—testicular cancer	0.000181	0.246	CbGdCrCtD
Etoposide—GSTT1—Glutathione conjugation—HPGDS—testicular cancer	0.000175	0.122	CbGpPWpGaD
Etoposide—TOP2A—testis—testicular cancer	0.000168	0.0229	CbGeAlD
Etoposide—TOP2B—lymph node—testicular cancer	0.000165	0.0225	CbGeAlD
Etoposide—ABCC3—female gonad—testicular cancer	0.000162	0.0221	CbGeAlD
Etoposide—GSTP1—female gonad—testicular cancer	0.000161	0.022	CbGeAlD
Etoposide—ABCC10—female gonad—testicular cancer	0.000161	0.022	CbGeAlD
Etoposide—ABCG2—seminal vesicle—testicular cancer	0.000161	0.0219	CbGeAlD
Etoposide—ABCC3—testis—testicular cancer	0.000144	0.0196	CbGeAlD
Etoposide—GSTP1—testis—testicular cancer	0.000143	0.0195	CbGeAlD
Etoposide—ABCC10—testis—testicular cancer	0.000143	0.0195	CbGeAlD
Etoposide—CYP2E1—seminal vesicle—testicular cancer	0.000139	0.019	CbGeAlD
Etoposide—PTGS2—embryo—testicular cancer	0.000136	0.0186	CbGeAlD
Etoposide—PTGS1—seminal vesicle—testicular cancer	0.000134	0.0183	CbGeAlD
Etoposide—PTGS2—seminal vesicle—testicular cancer	0.000128	0.0174	CbGeAlD
Etoposide—TOP2A—lymph node—testicular cancer	0.000122	0.0166	CbGeAlD
Etoposide—ABCC2—testis—testicular cancer	0.000115	0.0156	CbGeAlD
Etoposide—TOP2A—Vinorelbine—Vinblastine—testicular cancer	0.000114	0.155	CbGdCrCtD
Etoposide—ABCC1—female gonad—testicular cancer	0.000114	0.0155	CbGeAlD
Etoposide—ABCC3—lymph node—testicular cancer	0.000104	0.0142	CbGeAlD
Etoposide—GSTP1—lymph node—testicular cancer	0.000104	0.0141	CbGeAlD
Etoposide—ABCC10—lymph node—testicular cancer	0.000104	0.0141	CbGeAlD
Etoposide—ABCC1—testis—testicular cancer	0.000101	0.0138	CbGeAlD
Etoposide—TOP2A—Vincristine—Vinblastine—testicular cancer	9.76e-05	0.133	CbGdCrCtD
Etoposide—GSTP1—Glutathione conjugation—HPGDS—testicular cancer	9.59e-05	0.0669	CbGpPWpGaD
Etoposide—ABCG2—female gonad—testicular cancer	9.43e-05	0.0129	CbGeAlD
Etoposide—CYP3A5—female gonad—testicular cancer	8.76e-05	0.0119	CbGeAlD
Etoposide—CYP2C8—testis—testicular cancer	8.6e-05	0.0117	CbGeAlD
Etoposide—ABCB1—embryo—testicular cancer	8.43e-05	0.0115	CbGeAlD
Etoposide—ABCG2—testis—testicular cancer	8.37e-05	0.0114	CbGeAlD
Etoposide—ABCC2—lymph node—testicular cancer	8.32e-05	0.0113	CbGeAlD
Etoposide—ABCB1—seminal vesicle—testicular cancer	7.92e-05	0.0108	CbGeAlD
Etoposide—PTGS1—female gonad—testicular cancer	7.87e-05	0.0107	CbGeAlD
Etoposide—GSTP1—NRF2 pathway—SLC2A6—testicular cancer	7.84e-05	0.0548	CbGpPWpGaD
Etoposide—GSTT1—Phase II conjugation—HPGDS—testicular cancer	7.79e-05	0.0544	CbGpPWpGaD
Etoposide—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	7.6e-05	0.0531	CbGpPWpGaD
Etoposide—PTGS2—female gonad—testicular cancer	7.52e-05	0.0102	CbGeAlD
Etoposide—ABCC1—lymph node—testicular cancer	7.33e-05	0.00998	CbGeAlD
Etoposide—CYP2E1—testis—testicular cancer	7.24e-05	0.00987	CbGeAlD
Etoposide—PTGS1—testis—testicular cancer	6.98e-05	0.00951	CbGeAlD
Etoposide—ABCG2—lymph node—testicular cancer	6.06e-05	0.00826	CbGeAlD
Etoposide—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	6.04e-05	0.0421	CbGpPWpGaD
Etoposide—TOP2A—Doxorubicin—Epirubicin—testicular cancer	5.95e-05	0.0808	CbGdCrCtD
Etoposide—TOP2A—Daunorubicin—Epirubicin—testicular cancer	5.95e-05	0.0808	CbGdCrCtD
Etoposide—TOP2A—Idarubicin—Epirubicin—testicular cancer	5.95e-05	0.0808	CbGdCrCtD
Etoposide—ABCB1—gonad—testicular cancer	5.72e-05	0.0078	CbGeAlD
Etoposide—TOP2A—Epirubicin—Doxorubicin—testicular cancer	5.51e-05	0.0748	CbGdCrCtD
Etoposide—TOP2A—Idarubicin—Doxorubicin—testicular cancer	5.51e-05	0.0748	CbGdCrCtD
Etoposide—TOP2A—Daunorubicin—Doxorubicin—testicular cancer	5.51e-05	0.0748	CbGdCrCtD
Etoposide—PTGS1—lymph node—testicular cancer	5.06e-05	0.00689	CbGeAlD
Etoposide—ABCC3—NRF2 pathway—SLC2A6—testicular cancer	4.85e-05	0.0338	CbGpPWpGaD
Etoposide—PTGS2—lymph node—testicular cancer	4.83e-05	0.00659	CbGeAlD
Etoposide—ABCB1—female gonad—testicular cancer	4.65e-05	0.00634	CbGeAlD
Etoposide—ABCC6—Transmembrane transport of small molecules—SLC2A6—testicular cancer	4.58e-05	0.032	CbGpPWpGaD
Etoposide—GSTT1—Biological oxidations—HPGDS—testicular cancer	4.56e-05	0.0318	CbGpPWpGaD
Etoposide—GSTP1—Phase II conjugation—HPGDS—testicular cancer	4.27e-05	0.0298	CbGpPWpGaD
Etoposide—ABCB1—testis—testicular cancer	4.13e-05	0.00562	CbGeAlD
Etoposide—ABCC10—Transmembrane transport of small molecules—SLC2A6—testicular cancer	4.01e-05	0.028	CbGpPWpGaD
Etoposide—UGT1A1—NRF2 pathway—SLC2A6—testicular cancer	3.94e-05	0.0275	CbGpPWpGaD
Etoposide—ABCC2—NRF2 pathway—SLC2A6—testicular cancer	3.84e-05	0.0268	CbGpPWpGaD
Etoposide—ABCC1—Arachidonic acid metabolism—HPGDS—testicular cancer	3.25e-05	0.0227	CbGpPWpGaD
Etoposide—ABCB1—lymph node—testicular cancer	2.99e-05	0.00407	CbGeAlD
Etoposide—Anorexia—Cisplatin—testicular cancer	2.98e-05	0.000589	CcSEcCtD
Etoposide—Gastrointestinal pain—Ifosfamide—testicular cancer	2.96e-05	0.000586	CcSEcCtD
Etoposide—Toxic epidermal necrolysis—Epirubicin—testicular cancer	2.94e-05	0.000582	CcSEcCtD
Etoposide—Hypotension—Cisplatin—testicular cancer	2.92e-05	0.000578	CcSEcCtD
Etoposide—Hypersensitivity—Dactinomycin—testicular cancer	2.91e-05	0.000576	CcSEcCtD
Etoposide—Alanine aminotransferase increased—Epirubicin—testicular cancer	2.88e-05	0.00057	CcSEcCtD
Etoposide—Urticaria—Ifosfamide—testicular cancer	2.88e-05	0.00057	CcSEcCtD
Etoposide—Cardiac arrest—Doxorubicin—testicular cancer	2.87e-05	0.000568	CcSEcCtD
Etoposide—Abdominal pain—Ifosfamide—testicular cancer	2.86e-05	0.000567	CcSEcCtD
Etoposide—Body temperature increased—Ifosfamide—testicular cancer	2.86e-05	0.000567	CcSEcCtD
Etoposide—Pancytopenia—Methotrexate—testicular cancer	2.86e-05	0.000566	CcSEcCtD
Etoposide—Asthenia—Dactinomycin—testicular cancer	2.84e-05	0.000561	CcSEcCtD
Etoposide—Dysphagia—Epirubicin—testicular cancer	2.82e-05	0.000558	CcSEcCtD
Etoposide—Neutropenia—Methotrexate—testicular cancer	2.82e-05	0.000558	CcSEcCtD
Etoposide—Paraesthesia—Cisplatin—testicular cancer	2.8e-05	0.000555	CcSEcCtD
Etoposide—Dyspnoea—Cisplatin—testicular cancer	2.78e-05	0.000551	CcSEcCtD
Etoposide—PTGS1—Arachidonic acid metabolism—HPGDS—testicular cancer	2.75e-05	0.0192	CbGpPWpGaD
Etoposide—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	2.72e-05	0.000538	CcSEcCtD
Etoposide—Decreased appetite—Cisplatin—testicular cancer	2.71e-05	0.000537	CcSEcCtD
Etoposide—Diarrhoea—Dactinomycin—testicular cancer	2.7e-05	0.000535	CcSEcCtD
Etoposide—Pneumonia—Methotrexate—testicular cancer	2.7e-05	0.000535	CcSEcCtD
Etoposide—Gastrointestinal disorder—Cisplatin—testicular cancer	2.7e-05	0.000534	CcSEcCtD
Etoposide—Vomiting—Bleomycin—testicular cancer	2.7e-05	0.000533	CcSEcCtD
Etoposide—Infestation NOS—Methotrexate—testicular cancer	2.69e-05	0.000532	CcSEcCtD
Etoposide—Infestation—Methotrexate—testicular cancer	2.69e-05	0.000532	CcSEcCtD
Etoposide—Pancytopenia—Epirubicin—testicular cancer	2.68e-05	0.00053	CcSEcCtD
Etoposide—Rash—Bleomycin—testicular cancer	2.67e-05	0.000529	CcSEcCtD
Etoposide—Pain—Cisplatin—testicular cancer	2.67e-05	0.000529	CcSEcCtD
Etoposide—Dermatitis—Bleomycin—testicular cancer	2.67e-05	0.000528	CcSEcCtD
Etoposide—Hypersensitivity—Ifosfamide—testicular cancer	2.67e-05	0.000528	CcSEcCtD
Etoposide—Stevens-Johnson syndrome—Methotrexate—testicular cancer	2.66e-05	0.000527	CcSEcCtD
Etoposide—Alanine aminotransferase increased—Doxorubicin—testicular cancer	2.66e-05	0.000527	CcSEcCtD
Etoposide—Renal failure—Methotrexate—testicular cancer	2.64e-05	0.000523	CcSEcCtD
Etoposide—Neutropenia—Epirubicin—testicular cancer	2.64e-05	0.000522	CcSEcCtD
Etoposide—Stomatitis—Methotrexate—testicular cancer	2.62e-05	0.000518	CcSEcCtD
Etoposide—Dysphagia—Doxorubicin—testicular cancer	2.61e-05	0.000516	CcSEcCtD
Etoposide—Asthenia—Ifosfamide—testicular cancer	2.6e-05	0.000514	CcSEcCtD
Etoposide—Feeling abnormal—Cisplatin—testicular cancer	2.57e-05	0.000509	CcSEcCtD
Etoposide—Pruritus—Ifosfamide—testicular cancer	2.56e-05	0.000507	CcSEcCtD
Etoposide—Hepatobiliary disease—Methotrexate—testicular cancer	2.54e-05	0.000503	CcSEcCtD
Etoposide—Pneumonia—Epirubicin—testicular cancer	2.53e-05	0.000501	CcSEcCtD
Etoposide—Nausea—Bleomycin—testicular cancer	2.52e-05	0.000498	CcSEcCtD
Etoposide—Infestation—Epirubicin—testicular cancer	2.51e-05	0.000498	CcSEcCtD
Etoposide—Infestation NOS—Epirubicin—testicular cancer	2.51e-05	0.000498	CcSEcCtD
Etoposide—Vomiting—Dactinomycin—testicular cancer	2.51e-05	0.000497	CcSEcCtD
Etoposide—Agranulocytosis—Methotrexate—testicular cancer	2.51e-05	0.000496	CcSEcCtD
Etoposide—GSTP1—Biological oxidations—HPGDS—testicular cancer	2.5e-05	0.0174	CbGpPWpGaD
Etoposide—Stevens-Johnson syndrome—Epirubicin—testicular cancer	2.49e-05	0.000493	CcSEcCtD
Etoposide—Rash—Dactinomycin—testicular cancer	2.49e-05	0.000493	CcSEcCtD
Etoposide—Diarrhoea—Ifosfamide—testicular cancer	2.48e-05	0.000491	CcSEcCtD
Etoposide—Pancytopenia—Doxorubicin—testicular cancer	2.48e-05	0.00049	CcSEcCtD
Etoposide—Renal failure—Epirubicin—testicular cancer	2.47e-05	0.000489	CcSEcCtD
Etoposide—Body temperature increased—Cisplatin—testicular cancer	2.47e-05	0.000489	CcSEcCtD
Etoposide—Neuropathy peripheral—Epirubicin—testicular cancer	2.46e-05	0.000488	CcSEcCtD
Etoposide—Jaundice—Epirubicin—testicular cancer	2.45e-05	0.000485	CcSEcCtD
Etoposide—Stomatitis—Epirubicin—testicular cancer	2.45e-05	0.000485	CcSEcCtD
Etoposide—Neutropenia—Doxorubicin—testicular cancer	2.44e-05	0.000483	CcSEcCtD
Etoposide—Dizziness—Ifosfamide—testicular cancer	2.4e-05	0.000474	CcSEcCtD
Etoposide—Urinary tract disorder—Methotrexate—testicular cancer	2.38e-05	0.000471	CcSEcCtD
Etoposide—Hepatobiliary disease—Epirubicin—testicular cancer	2.38e-05	0.000471	CcSEcCtD
Etoposide—Urethral disorder—Methotrexate—testicular cancer	2.36e-05	0.000468	CcSEcCtD
Etoposide—Nausea—Dactinomycin—testicular cancer	2.35e-05	0.000465	CcSEcCtD
Etoposide—Agranulocytosis—Epirubicin—testicular cancer	2.35e-05	0.000464	CcSEcCtD
Etoposide—Pneumonia—Doxorubicin—testicular cancer	2.34e-05	0.000463	CcSEcCtD
Etoposide—PTGS2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	2.33e-05	0.0163	CbGpPWpGaD
Etoposide—Infestation—Doxorubicin—testicular cancer	2.33e-05	0.000461	CcSEcCtD
Etoposide—Infestation NOS—Doxorubicin—testicular cancer	2.33e-05	0.000461	CcSEcCtD
Etoposide—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	2.31e-05	0.000457	CcSEcCtD
Etoposide—Vomiting—Ifosfamide—testicular cancer	2.3e-05	0.000456	CcSEcCtD
Etoposide—Hypersensitivity—Cisplatin—testicular cancer	2.3e-05	0.000455	CcSEcCtD
Etoposide—Renal failure—Doxorubicin—testicular cancer	2.29e-05	0.000453	CcSEcCtD
Etoposide—Rash—Ifosfamide—testicular cancer	2.28e-05	0.000452	CcSEcCtD
Etoposide—Dermatitis—Ifosfamide—testicular cancer	2.28e-05	0.000452	CcSEcCtD
Etoposide—Erythema multiforme—Methotrexate—testicular cancer	2.28e-05	0.000451	CcSEcCtD
Etoposide—Neuropathy peripheral—Doxorubicin—testicular cancer	2.28e-05	0.000451	CcSEcCtD
Etoposide—Stomatitis—Doxorubicin—testicular cancer	2.27e-05	0.000449	CcSEcCtD
Etoposide—Jaundice—Doxorubicin—testicular cancer	2.27e-05	0.000449	CcSEcCtD
Etoposide—Eye disorder—Methotrexate—testicular cancer	2.25e-05	0.000446	CcSEcCtD
Etoposide—Hypoaesthesia—Epirubicin—testicular cancer	2.25e-05	0.000445	CcSEcCtD
Etoposide—Asthenia—Cisplatin—testicular cancer	2.24e-05	0.000443	CcSEcCtD
Etoposide—Cardiac disorder—Methotrexate—testicular cancer	2.24e-05	0.000443	CcSEcCtD
Etoposide—Urinary tract disorder—Epirubicin—testicular cancer	2.23e-05	0.000441	CcSEcCtD
Etoposide—Urethral disorder—Epirubicin—testicular cancer	2.21e-05	0.000438	CcSEcCtD
Etoposide—TOP2A—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	2.2e-05	0.0154	CbGpPWpGaD
Etoposide—Hepatobiliary disease—Doxorubicin—testicular cancer	2.2e-05	0.000436	CcSEcCtD
Etoposide—Angiopathy—Methotrexate—testicular cancer	2.19e-05	0.000433	CcSEcCtD
Etoposide—PTGS2—Arachidonic acid metabolism—HPGDS—testicular cancer	2.18e-05	0.0152	CbGpPWpGaD
Etoposide—Immune system disorder—Methotrexate—testicular cancer	2.18e-05	0.000431	CcSEcCtD
Etoposide—Mediastinal disorder—Methotrexate—testicular cancer	2.17e-05	0.00043	CcSEcCtD
Etoposide—Agranulocytosis—Doxorubicin—testicular cancer	2.17e-05	0.00043	CcSEcCtD
Etoposide—Chills—Methotrexate—testicular cancer	2.16e-05	0.000428	CcSEcCtD
Etoposide—Nausea—Ifosfamide—testicular cancer	2.15e-05	0.000426	CcSEcCtD
Etoposide—UGT1A1—Phase II conjugation—HPGDS—testicular cancer	2.14e-05	0.015	CbGpPWpGaD
Etoposide—Diarrhoea—Cisplatin—testicular cancer	2.14e-05	0.000423	CcSEcCtD
Etoposide—Erythema multiforme—Epirubicin—testicular cancer	2.13e-05	0.000422	CcSEcCtD
Etoposide—Alopecia—Methotrexate—testicular cancer	2.13e-05	0.000422	CcSEcCtD
Etoposide—Eye disorder—Epirubicin—testicular cancer	2.11e-05	0.000418	CcSEcCtD
Etoposide—Cardiac disorder—Epirubicin—testicular cancer	2.1e-05	0.000415	CcSEcCtD
Etoposide—Flushing—Epirubicin—testicular cancer	2.1e-05	0.000415	CcSEcCtD
Etoposide—Hypoaesthesia—Doxorubicin—testicular cancer	2.08e-05	0.000411	CcSEcCtD
Etoposide—Urinary tract disorder—Doxorubicin—testicular cancer	2.06e-05	0.000408	CcSEcCtD
Etoposide—Dysgeusia—Methotrexate—testicular cancer	2.06e-05	0.000407	CcSEcCtD
Etoposide—Angiopathy—Epirubicin—testicular cancer	2.05e-05	0.000405	CcSEcCtD
Etoposide—Urethral disorder—Doxorubicin—testicular cancer	2.05e-05	0.000405	CcSEcCtD
Etoposide—Immune system disorder—Epirubicin—testicular cancer	2.04e-05	0.000404	CcSEcCtD
Etoposide—Mediastinal disorder—Epirubicin—testicular cancer	2.03e-05	0.000403	CcSEcCtD
Etoposide—Back pain—Methotrexate—testicular cancer	2.03e-05	0.000402	CcSEcCtD
Etoposide—Chills—Epirubicin—testicular cancer	2.03e-05	0.000401	CcSEcCtD
Etoposide—Alopecia—Epirubicin—testicular cancer	1.99e-05	0.000395	CcSEcCtD
Etoposide—Vomiting—Cisplatin—testicular cancer	1.99e-05	0.000393	CcSEcCtD
Etoposide—Erythema multiforme—Doxorubicin—testicular cancer	1.97e-05	0.000391	CcSEcCtD
Etoposide—Rash—Cisplatin—testicular cancer	1.97e-05	0.00039	CcSEcCtD
Etoposide—Dermatitis—Cisplatin—testicular cancer	1.97e-05	0.000389	CcSEcCtD
Etoposide—Eye disorder—Doxorubicin—testicular cancer	1.95e-05	0.000386	CcSEcCtD
Etoposide—Ill-defined disorder—Methotrexate—testicular cancer	1.95e-05	0.000386	CcSEcCtD
Etoposide—Anaemia—Methotrexate—testicular cancer	1.94e-05	0.000384	CcSEcCtD
Etoposide—Flushing—Doxorubicin—testicular cancer	1.94e-05	0.000384	CcSEcCtD
Etoposide—Cardiac disorder—Doxorubicin—testicular cancer	1.94e-05	0.000384	CcSEcCtD
Etoposide—Dysgeusia—Epirubicin—testicular cancer	1.92e-05	0.000381	CcSEcCtD
Etoposide—Back pain—Epirubicin—testicular cancer	1.9e-05	0.000376	CcSEcCtD
Etoposide—Angiopathy—Doxorubicin—testicular cancer	1.9e-05	0.000375	CcSEcCtD
Etoposide—Malaise—Methotrexate—testicular cancer	1.89e-05	0.000375	CcSEcCtD
Etoposide—Muscle spasms—Epirubicin—testicular cancer	1.89e-05	0.000374	CcSEcCtD
Etoposide—Immune system disorder—Doxorubicin—testicular cancer	1.89e-05	0.000373	CcSEcCtD
Etoposide—Vertigo—Methotrexate—testicular cancer	1.89e-05	0.000373	CcSEcCtD
Etoposide—Mediastinal disorder—Doxorubicin—testicular cancer	1.88e-05	0.000373	CcSEcCtD
Etoposide—Leukopenia—Methotrexate—testicular cancer	1.88e-05	0.000372	CcSEcCtD
Etoposide—Chills—Doxorubicin—testicular cancer	1.87e-05	0.000371	CcSEcCtD
Etoposide—Nausea—Cisplatin—testicular cancer	1.86e-05	0.000367	CcSEcCtD
Etoposide—Alopecia—Doxorubicin—testicular cancer	1.85e-05	0.000365	CcSEcCtD
Etoposide—Cough—Methotrexate—testicular cancer	1.83e-05	0.000363	CcSEcCtD
Etoposide—Ill-defined disorder—Epirubicin—testicular cancer	1.82e-05	0.000361	CcSEcCtD
Etoposide—Convulsion—Methotrexate—testicular cancer	1.82e-05	0.00036	CcSEcCtD
Etoposide—Anaemia—Epirubicin—testicular cancer	1.82e-05	0.000359	CcSEcCtD
Etoposide—Chest pain—Methotrexate—testicular cancer	1.79e-05	0.000354	CcSEcCtD
Etoposide—Dysgeusia—Doxorubicin—testicular cancer	1.78e-05	0.000352	CcSEcCtD
Etoposide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	1.78e-05	0.000351	CcSEcCtD
Etoposide—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	1.77e-05	0.0124	CbGpPWpGaD
Etoposide—Malaise—Epirubicin—testicular cancer	1.77e-05	0.000351	CcSEcCtD
Etoposide—Discomfort—Methotrexate—testicular cancer	1.77e-05	0.00035	CcSEcCtD
Etoposide—Vertigo—Epirubicin—testicular cancer	1.77e-05	0.000349	CcSEcCtD
Etoposide—Leukopenia—Epirubicin—testicular cancer	1.76e-05	0.000348	CcSEcCtD
Etoposide—Back pain—Doxorubicin—testicular cancer	1.76e-05	0.000348	CcSEcCtD
Etoposide—Muscle spasms—Doxorubicin—testicular cancer	1.75e-05	0.000346	CcSEcCtD
Etoposide—Confusional state—Methotrexate—testicular cancer	1.73e-05	0.000342	CcSEcCtD
Etoposide—Loss of consciousness—Epirubicin—testicular cancer	1.73e-05	0.000342	CcSEcCtD
Etoposide—Cough—Epirubicin—testicular cancer	1.71e-05	0.000339	CcSEcCtD
Etoposide—Anaphylactic shock—Methotrexate—testicular cancer	1.71e-05	0.000339	CcSEcCtD
Etoposide—Convulsion—Epirubicin—testicular cancer	1.7e-05	0.000337	CcSEcCtD
Etoposide—Infection—Methotrexate—testicular cancer	1.7e-05	0.000337	CcSEcCtD
Etoposide—Hypertension—Epirubicin—testicular cancer	1.7e-05	0.000336	CcSEcCtD
Etoposide—Ill-defined disorder—Doxorubicin—testicular cancer	1.69e-05	0.000334	CcSEcCtD
Etoposide—Anaemia—Doxorubicin—testicular cancer	1.68e-05	0.000333	CcSEcCtD
Etoposide—Thrombocytopenia—Methotrexate—testicular cancer	1.68e-05	0.000332	CcSEcCtD
Etoposide—Chest pain—Epirubicin—testicular cancer	1.67e-05	0.000331	CcSEcCtD
Etoposide—Skin disorder—Methotrexate—testicular cancer	1.66e-05	0.000329	CcSEcCtD
Etoposide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	1.66e-05	0.000329	CcSEcCtD
Etoposide—Hyperhidrosis—Methotrexate—testicular cancer	1.66e-05	0.000328	CcSEcCtD
Etoposide—Discomfort—Epirubicin—testicular cancer	1.65e-05	0.000327	CcSEcCtD
Etoposide—Malaise—Doxorubicin—testicular cancer	1.64e-05	0.000325	CcSEcCtD
Etoposide—Vertigo—Doxorubicin—testicular cancer	1.63e-05	0.000323	CcSEcCtD
Etoposide—Anorexia—Methotrexate—testicular cancer	1.63e-05	0.000323	CcSEcCtD
Etoposide—Leukopenia—Doxorubicin—testicular cancer	1.63e-05	0.000322	CcSEcCtD
Etoposide—Confusional state—Epirubicin—testicular cancer	1.62e-05	0.00032	CcSEcCtD
Etoposide—TOP2A—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	1.61e-05	0.0112	CbGpPWpGaD
Etoposide—Anaphylactic shock—Epirubicin—testicular cancer	1.6e-05	0.000317	CcSEcCtD
Etoposide—Hypotension—Methotrexate—testicular cancer	1.6e-05	0.000317	CcSEcCtD
Etoposide—Loss of consciousness—Doxorubicin—testicular cancer	1.6e-05	0.000316	CcSEcCtD
Etoposide—Infection—Epirubicin—testicular cancer	1.59e-05	0.000315	CcSEcCtD
Etoposide—Cough—Doxorubicin—testicular cancer	1.59e-05	0.000314	CcSEcCtD
Etoposide—Convulsion—Doxorubicin—testicular cancer	1.58e-05	0.000312	CcSEcCtD
Etoposide—Thrombocytopenia—Epirubicin—testicular cancer	1.57e-05	0.000311	CcSEcCtD
Etoposide—Hypertension—Doxorubicin—testicular cancer	1.57e-05	0.000311	CcSEcCtD
Etoposide—Tachycardia—Epirubicin—testicular cancer	1.57e-05	0.00031	CcSEcCtD
Etoposide—Skin disorder—Epirubicin—testicular cancer	1.56e-05	0.000308	CcSEcCtD
Etoposide—ABCC3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.55e-05	0.0108	CbGpPWpGaD
Etoposide—Hyperhidrosis—Epirubicin—testicular cancer	1.55e-05	0.000307	CcSEcCtD
Etoposide—Chest pain—Doxorubicin—testicular cancer	1.55e-05	0.000306	CcSEcCtD
Etoposide—Paraesthesia—Methotrexate—testicular cancer	1.54e-05	0.000305	CcSEcCtD
Etoposide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	1.54e-05	0.000304	CcSEcCtD
Etoposide—Discomfort—Doxorubicin—testicular cancer	1.53e-05	0.000303	CcSEcCtD
Etoposide—Anorexia—Epirubicin—testicular cancer	1.53e-05	0.000303	CcSEcCtD
Etoposide—Dyspnoea—Methotrexate—testicular cancer	1.53e-05	0.000302	CcSEcCtD
Etoposide—Somnolence—Methotrexate—testicular cancer	1.52e-05	0.000302	CcSEcCtD
Etoposide—PTGS2—C-MYB transcription factor network—MAD1L1—testicular cancer	1.51e-05	0.0105	CbGpPWpGaD
Etoposide—Hypotension—Epirubicin—testicular cancer	1.5e-05	0.000297	CcSEcCtD
Etoposide—Confusional state—Doxorubicin—testicular cancer	1.5e-05	0.000296	CcSEcCtD
Etoposide—Decreased appetite—Methotrexate—testicular cancer	1.49e-05	0.000295	CcSEcCtD
Etoposide—Anaphylactic shock—Doxorubicin—testicular cancer	1.48e-05	0.000294	CcSEcCtD
Etoposide—Gastrointestinal disorder—Methotrexate—testicular cancer	1.48e-05	0.000293	CcSEcCtD
Etoposide—Fatigue—Methotrexate—testicular cancer	1.48e-05	0.000292	CcSEcCtD
Etoposide—Infection—Doxorubicin—testicular cancer	1.47e-05	0.000292	CcSEcCtD
Etoposide—Pain—Methotrexate—testicular cancer	1.47e-05	0.00029	CcSEcCtD
Etoposide—Thrombocytopenia—Doxorubicin—testicular cancer	1.45e-05	0.000288	CcSEcCtD
Etoposide—Tachycardia—Doxorubicin—testicular cancer	1.45e-05	0.000287	CcSEcCtD
Etoposide—Skin disorder—Doxorubicin—testicular cancer	1.44e-05	0.000285	CcSEcCtD
Etoposide—Paraesthesia—Epirubicin—testicular cancer	1.44e-05	0.000285	CcSEcCtD
Etoposide—Hyperhidrosis—Doxorubicin—testicular cancer	1.43e-05	0.000284	CcSEcCtD
Etoposide—Dyspnoea—Epirubicin—testicular cancer	1.43e-05	0.000283	CcSEcCtD
Etoposide—Somnolence—Epirubicin—testicular cancer	1.43e-05	0.000282	CcSEcCtD
Etoposide—Anorexia—Doxorubicin—testicular cancer	1.41e-05	0.00028	CcSEcCtD
Etoposide—Feeling abnormal—Methotrexate—testicular cancer	1.41e-05	0.00028	CcSEcCtD
Etoposide—Gastrointestinal pain—Methotrexate—testicular cancer	1.4e-05	0.000277	CcSEcCtD
Etoposide—Decreased appetite—Epirubicin—testicular cancer	1.39e-05	0.000276	CcSEcCtD
Etoposide—Hypotension—Doxorubicin—testicular cancer	1.39e-05	0.000274	CcSEcCtD
Etoposide—Gastrointestinal disorder—Epirubicin—testicular cancer	1.38e-05	0.000274	CcSEcCtD
Etoposide—Fatigue—Epirubicin—testicular cancer	1.38e-05	0.000274	CcSEcCtD
Etoposide—Pain—Epirubicin—testicular cancer	1.37e-05	0.000271	CcSEcCtD
Etoposide—Constipation—Epirubicin—testicular cancer	1.37e-05	0.000271	CcSEcCtD
Etoposide—Urticaria—Methotrexate—testicular cancer	1.36e-05	0.000269	CcSEcCtD
Etoposide—Body temperature increased—Methotrexate—testicular cancer	1.35e-05	0.000268	CcSEcCtD
Etoposide—Abdominal pain—Methotrexate—testicular cancer	1.35e-05	0.000268	CcSEcCtD
Etoposide—Paraesthesia—Doxorubicin—testicular cancer	1.33e-05	0.000264	CcSEcCtD
Etoposide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	1.33e-05	0.0093	CbGpPWpGaD
Etoposide—Dyspnoea—Doxorubicin—testicular cancer	1.32e-05	0.000262	CcSEcCtD
Etoposide—Feeling abnormal—Epirubicin—testicular cancer	1.32e-05	0.000262	CcSEcCtD
Etoposide—Somnolence—Doxorubicin—testicular cancer	1.32e-05	0.000261	CcSEcCtD
Etoposide—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	1.32e-05	0.0092	CbGpPWpGaD
Etoposide—Gastrointestinal pain—Epirubicin—testicular cancer	1.31e-05	0.00026	CcSEcCtD
Etoposide—GSTP1—Cellular responses to stress—H2AFZ—testicular cancer	1.3e-05	0.00904	CbGpPWpGaD
Etoposide—Decreased appetite—Doxorubicin—testicular cancer	1.29e-05	0.000255	CcSEcCtD
Etoposide—Gastrointestinal disorder—Doxorubicin—testicular cancer	1.28e-05	0.000254	CcSEcCtD
Etoposide—Fatigue—Doxorubicin—testicular cancer	1.28e-05	0.000253	CcSEcCtD
Etoposide—Urticaria—Epirubicin—testicular cancer	1.27e-05	0.000252	CcSEcCtD
Etoposide—Constipation—Doxorubicin—testicular cancer	1.27e-05	0.000251	CcSEcCtD
Etoposide—Pain—Doxorubicin—testicular cancer	1.27e-05	0.000251	CcSEcCtD
Etoposide—Abdominal pain—Epirubicin—testicular cancer	1.27e-05	0.000251	CcSEcCtD
Etoposide—Body temperature increased—Epirubicin—testicular cancer	1.27e-05	0.000251	CcSEcCtD
Etoposide—Hypersensitivity—Methotrexate—testicular cancer	1.26e-05	0.00025	CcSEcCtD
Etoposide—UGT1A1—Biological oxidations—HPGDS—testicular cancer	1.25e-05	0.00875	CbGpPWpGaD
Etoposide—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	1.23e-05	0.00861	CbGpPWpGaD
Etoposide—ABCC2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.23e-05	0.00859	CbGpPWpGaD
Etoposide—Asthenia—Methotrexate—testicular cancer	1.23e-05	0.000243	CcSEcCtD
Etoposide—Feeling abnormal—Doxorubicin—testicular cancer	1.22e-05	0.000242	CcSEcCtD
Etoposide—ABCC1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.22e-05	0.00849	CbGpPWpGaD
Etoposide—Gastrointestinal pain—Doxorubicin—testicular cancer	1.21e-05	0.00024	CcSEcCtD
Etoposide—Pruritus—Methotrexate—testicular cancer	1.21e-05	0.00024	CcSEcCtD
Etoposide—Hypersensitivity—Epirubicin—testicular cancer	1.18e-05	0.000234	CcSEcCtD
Etoposide—Urticaria—Doxorubicin—testicular cancer	1.18e-05	0.000233	CcSEcCtD
Etoposide—Abdominal pain—Doxorubicin—testicular cancer	1.17e-05	0.000232	CcSEcCtD
Etoposide—Body temperature increased—Doxorubicin—testicular cancer	1.17e-05	0.000232	CcSEcCtD
Etoposide—Diarrhoea—Methotrexate—testicular cancer	1.17e-05	0.000232	CcSEcCtD
Etoposide—TOP2A—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	1.17e-05	0.00815	CbGpPWpGaD
Etoposide—Asthenia—Epirubicin—testicular cancer	1.15e-05	0.000228	CcSEcCtD
Etoposide—Pruritus—Epirubicin—testicular cancer	1.13e-05	0.000225	CcSEcCtD
Etoposide—Dizziness—Methotrexate—testicular cancer	1.13e-05	0.000224	CcSEcCtD
Etoposide—Diarrhoea—Epirubicin—testicular cancer	1.1e-05	0.000217	CcSEcCtD
Etoposide—Hypersensitivity—Doxorubicin—testicular cancer	1.09e-05	0.000216	CcSEcCtD
Etoposide—Vomiting—Methotrexate—testicular cancer	1.09e-05	0.000216	CcSEcCtD
Etoposide—Rash—Methotrexate—testicular cancer	1.08e-05	0.000214	CcSEcCtD
Etoposide—Dermatitis—Methotrexate—testicular cancer	1.08e-05	0.000214	CcSEcCtD
Etoposide—Headache—Methotrexate—testicular cancer	1.07e-05	0.000212	CcSEcCtD
Etoposide—ABCG2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.07e-05	0.00747	CbGpPWpGaD
Etoposide—Asthenia—Doxorubicin—testicular cancer	1.06e-05	0.000211	CcSEcCtD
Etoposide—Dizziness—Epirubicin—testicular cancer	1.06e-05	0.00021	CcSEcCtD
Etoposide—PTGS2—C-MYB transcription factor network—H2AFZ—testicular cancer	1.05e-05	0.00734	CbGpPWpGaD
Etoposide—Pruritus—Doxorubicin—testicular cancer	1.05e-05	0.000208	CcSEcCtD
Etoposide—PTGS1—Biological oxidations—HPGDS—testicular cancer	1.02e-05	0.00713	CbGpPWpGaD
Etoposide—Vomiting—Epirubicin—testicular cancer	1.02e-05	0.000202	CcSEcCtD
Etoposide—Nausea—Methotrexate—testicular cancer	1.02e-05	0.000201	CcSEcCtD
Etoposide—Diarrhoea—Doxorubicin—testicular cancer	1.02e-05	0.000201	CcSEcCtD
Etoposide—Rash—Epirubicin—testicular cancer	1.01e-05	0.0002	CcSEcCtD
Etoposide—Dermatitis—Epirubicin—testicular cancer	1.01e-05	0.0002	CcSEcCtD
Etoposide—Headache—Epirubicin—testicular cancer	1e-05	0.000199	CcSEcCtD
Etoposide—Dizziness—Doxorubicin—testicular cancer	9.81e-06	0.000194	CcSEcCtD
Etoposide—PTGS2—C-MYB transcription factor network—KITLG—testicular cancer	9.68e-06	0.00675	CbGpPWpGaD
Etoposide—Nausea—Epirubicin—testicular cancer	9.53e-06	0.000189	CcSEcCtD
Etoposide—Vomiting—Doxorubicin—testicular cancer	9.44e-06	0.000187	CcSEcCtD
Etoposide—Rash—Doxorubicin—testicular cancer	9.36e-06	0.000185	CcSEcCtD
Etoposide—Dermatitis—Doxorubicin—testicular cancer	9.35e-06	0.000185	CcSEcCtD
Etoposide—Headache—Doxorubicin—testicular cancer	9.3e-06	0.000184	CcSEcCtD
Etoposide—Nausea—Doxorubicin—testicular cancer	8.81e-06	0.000174	CcSEcCtD
Etoposide—TOP2A—Cell Cycle, Mitotic—MAD1L1—testicular cancer	8.15e-06	0.00569	CbGpPWpGaD
Etoposide—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	7.85e-06	0.00548	CbGpPWpGaD
Etoposide—GSTT1—Metabolism—HPGDS—testicular cancer	7.79e-06	0.00544	CbGpPWpGaD
Etoposide—CYP2E1—Biological oxidations—HPGDS—testicular cancer	7.64e-06	0.00533	CbGpPWpGaD
Etoposide—CYP3A5—Biological oxidations—HPGDS—testicular cancer	7.62e-06	0.00532	CbGpPWpGaD
Etoposide—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	7.46e-06	0.00521	CbGpPWpGaD
Etoposide—TOP2A—Cell Cycle—MAD1L1—testicular cancer	7.29e-06	0.00509	CbGpPWpGaD
Etoposide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	7.2e-06	0.00503	CbGpPWpGaD
Etoposide—PTGS2—C-MYB transcription factor network—KIT—testicular cancer	6.6e-06	0.00461	CbGpPWpGaD
Etoposide—CYP2C8—Biological oxidations—HPGDS—testicular cancer	6.6e-06	0.00461	CbGpPWpGaD
Etoposide—ABCC3—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	5.92e-06	0.00414	CbGpPWpGaD
Etoposide—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	5.79e-06	0.00404	CbGpPWpGaD
Etoposide—TOP2A—Cell Cycle, Mitotic—H2AFZ—testicular cancer	5.68e-06	0.00397	CbGpPWpGaD
Etoposide—GSTT1—Metabolism—STK11—testicular cancer	5.66e-06	0.00395	CbGpPWpGaD
Etoposide—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	5.42e-06	0.00378	CbGpPWpGaD
Etoposide—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	5.29e-06	0.00369	CbGpPWpGaD
Etoposide—TOP2A—Cell Cycle—H2AFZ—testicular cancer	5.08e-06	0.00355	CbGpPWpGaD
Etoposide—ABCC1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	4.64e-06	0.00324	CbGpPWpGaD
Etoposide—CYP1A2—Biological oxidations—HPGDS—testicular cancer	4.59e-06	0.0032	CbGpPWpGaD
Etoposide—GSTP1—Metabolism—HPGDS—testicular cancer	4.27e-06	0.00298	CbGpPWpGaD
Etoposide—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.92e-06	0.00274	CbGpPWpGaD
Etoposide—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	3.84e-06	0.00268	CbGpPWpGaD
Etoposide—CYP3A4—Biological oxidations—HPGDS—testicular cancer	3.54e-06	0.00247	CbGpPWpGaD
Etoposide—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.12e-06	0.00217	CbGpPWpGaD
Etoposide—GSTP1—Metabolism—STK11—testicular cancer	3.1e-06	0.00217	CbGpPWpGaD
Etoposide—ABCC3—Metabolism—HPGDS—testicular cancer	2.64e-06	0.00184	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.53e-06	0.00177	CbGpPWpGaD
Etoposide—UGT1A1—Metabolism—HPGDS—testicular cancer	2.14e-06	0.0015	CbGpPWpGaD
Etoposide—ABCC1—Metabolism—HPGDS—testicular cancer	2.07e-06	0.00144	CbGpPWpGaD
Etoposide—ABCC3—Metabolism—STK11—testicular cancer	1.92e-06	0.00134	CbGpPWpGaD
Etoposide—ABCG2—Metabolism—HPGDS—testicular cancer	1.82e-06	0.00127	CbGpPWpGaD
Etoposide—ABCC1—Disease—H2AFZ—testicular cancer	1.8e-06	0.00126	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.76e-06	0.00123	CbGpPWpGaD
Etoposide—PTGS1—Metabolism—HPGDS—testicular cancer	1.75e-06	0.00122	CbGpPWpGaD
Etoposide—ABCC1—Disease—KITLG—testicular cancer	1.66e-06	0.00116	CbGpPWpGaD
Etoposide—UGT1A1—Metabolism—STK11—testicular cancer	1.56e-06	0.00109	CbGpPWpGaD
Etoposide—ABCC1—Metabolism—STK11—testicular cancer	1.5e-06	0.00105	CbGpPWpGaD
Etoposide—PTGS2—Metabolism—HPGDS—testicular cancer	1.39e-06	0.000968	CbGpPWpGaD
Etoposide—ABCG2—Metabolism—STK11—testicular cancer	1.32e-06	0.000923	CbGpPWpGaD
Etoposide—CYP2E1—Metabolism—HPGDS—testicular cancer	1.31e-06	0.000912	CbGpPWpGaD
Etoposide—CYP3A5—Metabolism—HPGDS—testicular cancer	1.3e-06	0.00091	CbGpPWpGaD
Etoposide—PTGS1—Metabolism—STK11—testicular cancer	1.27e-06	0.000886	CbGpPWpGaD
Etoposide—ABCC1—Disease—FGFR3—testicular cancer	1.23e-06	0.000861	CbGpPWpGaD
Etoposide—PTGS2—Disease—H2AFZ—testicular cancer	1.21e-06	0.000845	CbGpPWpGaD
Etoposide—ABCC1—Disease—KIT—testicular cancer	1.13e-06	0.00079	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—HPGDS—testicular cancer	1.13e-06	0.000788	CbGpPWpGaD
Etoposide—PTGS2—Disease—KITLG—testicular cancer	1.11e-06	0.000777	CbGpPWpGaD
Etoposide—PTGS2—Metabolism—STK11—testicular cancer	1.01e-06	0.000704	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—HPGDS—testicular cancer	9.83e-07	0.000687	CbGpPWpGaD
Etoposide—CYP2E1—Metabolism—STK11—testicular cancer	9.49e-07	0.000662	CbGpPWpGaD
Etoposide—CYP3A5—Metabolism—STK11—testicular cancer	9.47e-07	0.000661	CbGpPWpGaD
Etoposide—PTGS2—Disease—FGFR3—testicular cancer	8.28e-07	0.000578	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—STK11—testicular cancer	8.2e-07	0.000573	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—HPGDS—testicular cancer	7.85e-07	0.000548	CbGpPWpGaD
Etoposide—PTGS2—Disease—KIT—testicular cancer	7.6e-07	0.00053	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—STK11—testicular cancer	7.15e-07	0.000499	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—HPGDS—testicular cancer	6.06e-07	0.000423	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—STK11—testicular cancer	5.7e-07	0.000398	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—STK11—testicular cancer	4.4e-07	0.000307	CbGpPWpGaD
